Latest Ratios: P/E Ratio -0.6x · EV/EBITDA N/A · ROE -103.6%. (1995–2024 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $4M | $3M | $6M | $10M | $41M | $131M | $186M | $150M | $565M | $1.7B | $1.8B |
| Enterprise Value | $1M | $99740 | $9000 | $8M | $35M | $127M | $186M | $145M | $564M | $1.7B | $1.8B |
| P/E Ratio → | -0.59 | — | — | — | — | — | — | — | — | 399.89 | — |
| P/S Ratio | — | — | 6204.00 | 174.64 | 26.71 | 27.17 | 51.65 | 25.40 | 2625.78 | 113.95 | 1065.64 |
| P/B Ratio | 1.13 | 1.20 | 0.93 | 7.69 | 7.93 | 37.22 | 130.15 | 21.98 | 658.74 | 130.13 | 254.75 |
| P/FCF | — | — | — | — | — | — | — | — | — | 280.40 | — |
| P/OCF | — | — | — | — | — | — | — | — | — | 272.78 | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | 9.00 | 128.81 | 22.95 | 26.22 | 51.43 | 24.56 | 2621.42 | 113.02 | 1060.94 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | 360.72 | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | 392.03 | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | 278.11 | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | 100.0% | -226.7% | 87.0% | 90.2% | 64.3% | 90.9% | -4387.4% | 59.3% | -179.8% |
| Operating Margin | — | — | -727700.0% | -17058.3% | -613.0% | -151.9% | -466.5% | -139.8% | -6745.1% | 28.8% | -404.5% |
| Net Profit Margin | — | — | -556900.0% | -16961.7% | -531.7% | -428.4% | -445.6% | -152.6% | -6654.4% | 34.1% | -675.0% |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -103.6% | -103.6% | -139.1% | -313.1% | -187.2% | -835.0% | -389.4% | -234.7% | -203.7% | 50.9% | -144.6% |
| ROA | -85.5% | -85.5% | -91.7% | -168.9% | -100.9% | -235.4% | -136.2% | -78.5% | -103.8% | 32.1% | -66.1% |
| ROIC | -12206.3% | -12206.3% | — | — | — | — | -1010.2% | -700.7% | — | — | — |
| ROCE | -100.4% | -100.4% | -180.3% | -303.1% | -203.6% | -150.2% | -203.4% | -109.6% | -158.9% | 39.0% | -59.8% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 0.09 | 0.14 | 0.06 | 0.23 | 3.10 | 0.63 | 7.68 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.16 | -0.93 | -2.02 | -1.12 | -1.30 | -0.55 | -0.73 | -1.09 | -1.06 | -1.12 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | -2.97 | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | -2.29 | — |
| Interest Coverage | — | — | — | — | — | -9.56 | -17.42 | -9.32 | -39.30 | 117.38 | — |
Net cash position: cash ($3M) exceeds total debt ($0)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.05 | 6.05 | 5.55 | 1.37 | 2.71 | 1.74 | 2.31 | 3.85 | 1.86 | 3.67 | 2.52 |
| Quick Ratio | 6.05 | 6.05 | 5.55 | 1.33 | 2.60 | 1.66 | 2.03 | 3.49 | 1.86 | 3.67 | 2.52 |
| Cash Ratio | 5.86 | 5.86 | 4.68 | 1.12 | 2.26 | 1.28 | 1.45 | 2.69 | 1.69 | 2.88 | 1.62 |
| Asset Turnover | — | — | 0.00 | 0.01 | 0.19 | 0.60 | 0.38 | 0.42 | 0.02 | 0.81 | 0.13 |
| Inventory Turnover | 1.85 | — | — | 1.85 | 0.68 | 1.44 | 1.29 | 0.43 | — | — | — |
| Days Sales Outstanding | — | — | 381790.00 | 219.00 | 26.79 | 66.69 | 44.27 | 113.37 | 110.35 | 86.91 | 920.25 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | 0.2% | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | 0.3% | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | 0.4% | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.2% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $899000 | $752000 | $671700 | $2M | $2M | $2M | $189598 | $117908 | $119208 | $111404 |
Imminent liquidity insolvency risk
According to recent market data, Titan Pharmaceuticals trades at a price-to-book ratio of 1.13, a valuation level that suggests investors are pricing in a high probability of terminal dilution or insolvency rather than any meaningful future growth from the company's proprietary ProNeura drug delivery platform.
The lack of meaningful P/E or P/S multiples confirms the market's view of the firm as a distressed asset rather than a going concern. This valuation gap relative to peers indicates that the market has largely abandoned the prospect of commercial success for the current pipeline.
As reported in financial statements, the company's profitability metrics remain deeply negative, with recent quarterly ROE figures of -29.5% highlighting a structural inability to generate returns on invested capital in the absence of a functional commercial revenue stream or scalable product sales.
The consistent negative margins suggest that the firm's cost structure is entirely disconnected from revenue generation. Without a pivot to a licensing-only model, the current operating profile appears unsustainable and continues to erode shareholder equity at an accelerating pace.
Based on historical data, the company's asset turnover has effectively collapsed to zero, reflecting a complete cessation of commercial activity and an inability to leverage the firm's remaining intellectual property into meaningful revenue-generating operations or efficient working capital cycles.
The lack of meaningful DSO or CCC metrics underscores the firm's transition into a pure R&D entity with no operational throughput. This stagnation implies that management is currently unable to convert clinical progress into the cash-generating efficiency required to sustain long-term corporate viability.
As indicated by the most recent quarterly filings, the company's current ratio of 11.60 is misleading, as it masks a critical lack of liquid assets relative to the ongoing cash burn required to maintain the firm's regulatory and clinical compliance obligations.
While the current ratio appears high, the absolute cash balance of $2.8 million is insufficient to support the company's fixed cost base for an extended period. This liquidity position warrants extreme caution, as it suggests that the firm is nearing a point of operational exhaustion.
Investors frequently misapply the current ratio to this business model, failing to recognize that in a pre-revenue biotech firm, high liquidity ratios often reflect the final stages of capital depletion rather than a healthy ability to meet short-term obligations through operational cash flow.
The current ratio obscures the reality that the company lacks a self-sustaining revenue engine, making it entirely dependent on external financing. A more appropriate metric for this firm would be the 'Cash Runway to Milestone' ratio, which directly measures the survival time remaining before the next necessary capital raise.
Includes 30+ ratios · 30 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying TTNP stock.
Titan Pharmaceuticals, Inc.'s current P/E ratio is -0.6x. The historical average is 127.2x.
Titan Pharmaceuticals, Inc.'s return on equity (ROE) is -103.6%. The historical average is -109.1%.
Based on historical data, Titan Pharmaceuticals, Inc. is trading at a P/E of -0.6x. Compare with industry peers and growth rates for a complete picture.